Loading…

The stakes of pre- and post-market authorization development and clinical assessment

Saved in:

Bibliographic Details
Published in:	La Presse médicale (1983) 2012-05, Vol.41 Suppl 1, p.S6-S8
Main Author:	Schwebig, Annick
Format:	Article
Language:	fre
Subjects:	Biomedical Research - legislation & jurisprudence Biomedical Research - methods Clinical Trials as Topic - legislation & jurisprudence Clinical Trials as Topic - methods Clinical Trials as Topic - standards Drug Approval - methods Drug Approval - organization & administration Drug Discovery - economics Drug Discovery - methods Drug Discovery - organization & administration Humans Orphan Drug Production - methods Orphan Drug Production - standards Product Surveillance, Postmarketing - methods Product Surveillance, Postmarketing - standards Rare Diseases - diagnosis Rare Diseases - etiology Rare Diseases - physiopathology Rare Diseases - therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites
container_end_page	S8
container_issue
container_start_page	S6
container_title	La Presse médicale (1983)
container_volume	41 Suppl 1
creator	Schwebig, Annick
description
doi_str_mv	10.1016/j.lpm.2012.02.026
format	article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1015093287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1015093287</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-9092d2cc3dc16e694a24e07d19b13d901d2377b811858ad98a5aed1cfea977f23</originalsourceid><addsrcrecordid>eNo1kF9LwzAUxYMgbk4_gC-SR19ac5OuaR5l-A8GvsznkiW3rFvaxCYV9NPb6YQDBw4_DvceQm6A5cCgvN_nLnQ5Z8BzdlR5Ruacg8gYl-WMXMa4Z4xDIdUFmXFeVEJKNiebzQ5pTPqAkfqGhgEzqntLg48p6_RwwET1mHZ-aL91an1PLX6i86HDPv2SxrV9a7SjOkaM8ZhfkfNGu4jXJ1-Q96fHzeolW789v64e1lmAAlKmmOKWGyOsgRJLVWheIJMW1BaEVQwsn47cVgDVstJWVXqp0YJpUCspGy4W5O6vNwz-Y8SY6q6NBp3TPfox1tMwS6YEr-SE3p7QcduhrcPQTt991f9LiB9mNl-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1015093287</pqid></control><display><type>article</type><title>The stakes of pre- and post-market authorization development and clinical assessment</title><source>ScienceDirect Journals</source><creator>Schwebig, Annick</creator><creatorcontrib>Schwebig, Annick</creatorcontrib><identifier>EISSN: 2213-0276</identifier><identifier>DOI: 10.1016/j.lpm.2012.02.026</identifier><identifier>PMID: 22483770</identifier><language>fre</language><publisher>France</publisher><subject>Biomedical Research - legislation & jurisprudence ; Biomedical Research - methods ; Clinical Trials as Topic - legislation & jurisprudence ; Clinical Trials as Topic - methods ; Clinical Trials as Topic - standards ; Drug Approval - methods ; Drug Approval - organization & administration ; Drug Discovery - economics ; Drug Discovery - methods ; Drug Discovery - organization & administration ; Humans ; Orphan Drug Production - methods ; Orphan Drug Production - standards ; Product Surveillance, Postmarketing - methods ; Product Surveillance, Postmarketing - standards ; Rare Diseases - diagnosis ; Rare Diseases - etiology ; Rare Diseases - physiopathology ; Rare Diseases - therapy</subject><ispartof>La Presse médicale (1983), 2012-05, Vol.41 Suppl 1, p.S6-S8</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22483770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwebig, Annick</creatorcontrib><title>The stakes of pre- and post-market authorization development and clinical assessment</title><title>La Presse médicale (1983)</title><addtitle>Presse Med</addtitle><subject>Biomedical Research - legislation & jurisprudence</subject><subject>Biomedical Research - methods</subject><subject>Clinical Trials as Topic - legislation & jurisprudence</subject><subject>Clinical Trials as Topic - methods</subject><subject>Clinical Trials as Topic - standards</subject><subject>Drug Approval - methods</subject><subject>Drug Approval - organization & administration</subject><subject>Drug Discovery - economics</subject><subject>Drug Discovery - methods</subject><subject>Drug Discovery - organization & administration</subject><subject>Humans</subject><subject>Orphan Drug Production - methods</subject><subject>Orphan Drug Production - standards</subject><subject>Product Surveillance, Postmarketing - methods</subject><subject>Product Surveillance, Postmarketing - standards</subject><subject>Rare Diseases - diagnosis</subject><subject>Rare Diseases - etiology</subject><subject>Rare Diseases - physiopathology</subject><subject>Rare Diseases - therapy</subject><issn>2213-0276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNo1kF9LwzAUxYMgbk4_gC-SR19ac5OuaR5l-A8GvsznkiW3rFvaxCYV9NPb6YQDBw4_DvceQm6A5cCgvN_nLnQ5Z8BzdlR5Ruacg8gYl-WMXMa4Z4xDIdUFmXFeVEJKNiebzQ5pTPqAkfqGhgEzqntLg48p6_RwwET1mHZ-aL91an1PLX6i86HDPv2SxrV9a7SjOkaM8ZhfkfNGu4jXJ1-Q96fHzeolW789v64e1lmAAlKmmOKWGyOsgRJLVWheIJMW1BaEVQwsn47cVgDVstJWVXqp0YJpUCspGy4W5O6vNwz-Y8SY6q6NBp3TPfox1tMwS6YEr-SE3p7QcduhrcPQTt991f9LiB9mNl-A</recordid><startdate>201205</startdate><enddate>201205</enddate><creator>Schwebig, Annick</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201205</creationdate><title>The stakes of pre- and post-market authorization development and clinical assessment</title><author>Schwebig, Annick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-9092d2cc3dc16e694a24e07d19b13d901d2377b811858ad98a5aed1cfea977f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2012</creationdate><topic>Biomedical Research - legislation & jurisprudence</topic><topic>Biomedical Research - methods</topic><topic>Clinical Trials as Topic - legislation & jurisprudence</topic><topic>Clinical Trials as Topic - methods</topic><topic>Clinical Trials as Topic - standards</topic><topic>Drug Approval - methods</topic><topic>Drug Approval - organization & administration</topic><topic>Drug Discovery - economics</topic><topic>Drug Discovery - methods</topic><topic>Drug Discovery - organization & administration</topic><topic>Humans</topic><topic>Orphan Drug Production - methods</topic><topic>Orphan Drug Production - standards</topic><topic>Product Surveillance, Postmarketing - methods</topic><topic>Product Surveillance, Postmarketing - standards</topic><topic>Rare Diseases - diagnosis</topic><topic>Rare Diseases - etiology</topic><topic>Rare Diseases - physiopathology</topic><topic>Rare Diseases - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwebig, Annick</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>La Presse médicale (1983)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwebig, Annick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The stakes of pre- and post-market authorization development and clinical assessment</atitle><jtitle>La Presse médicale (1983)</jtitle><addtitle>Presse Med</addtitle><date>2012-05</date><risdate>2012</risdate><volume>41 Suppl 1</volume><spage>S6</spage><epage>S8</epage><pages>S6-S8</pages><eissn>2213-0276</eissn><cop>France</cop><pmid>22483770</pmid><doi>10.1016/j.lpm.2012.02.026</doi></addata></record>
fulltext	fulltext
identifier	EISSN: 2213-0276
ispartof	La Presse médicale (1983), 2012-05, Vol.41 Suppl 1, p.S6-S8
issn	2213-0276
language	fre
recordid	cdi_proquest_miscellaneous_1015093287
source	ScienceDirect Journals
subjects	Biomedical Research - legislation & jurisprudence Biomedical Research - methods Clinical Trials as Topic - legislation & jurisprudence Clinical Trials as Topic - methods Clinical Trials as Topic - standards Drug Approval - methods Drug Approval - organization & administration Drug Discovery - economics Drug Discovery - methods Drug Discovery - organization & administration Humans Orphan Drug Production - methods Orphan Drug Production - standards Product Surveillance, Postmarketing - methods Product Surveillance, Postmarketing - standards Rare Diseases - diagnosis Rare Diseases - etiology Rare Diseases - physiopathology Rare Diseases - therapy
title	The stakes of pre- and post-market authorization development and clinical assessment
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A37%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20stakes%20of%20pre-%20and%20post-market%20authorization%20development%20and%20clinical%20assessment&rft.jtitle=La%20Presse%20m%C3%A9dicale%20(1983)&rft.au=Schwebig,%20Annick&rft.date=2012-05&rft.volume=41%20Suppl%201&rft.spage=S6&rft.epage=S8&rft.pages=S6-S8&rft.eissn=2213-0276&rft_id=info:doi/10.1016/j.lpm.2012.02.026&rft_dat=%3Cproquest_pubme%3E1015093287%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p141t-9092d2cc3dc16e694a24e07d19b13d901d2377b811858ad98a5aed1cfea977f23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1015093287&rft_id=info:pmid/22483770&rfr_iscdi=true